NCT07910019Recruiting
Evaluating Prostate Cancer Patient Natural Killer Cell Function Across Racial Background and Addressing Functional Disparities With Trispecific Killer Engagers
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
This study collects, stores and analyzes blood specimens and information from people with prostate cancer. This may help researchers understand whether certain white blood cells involved in immunity differs between prostate cancer patients from various racial backgrounds.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 45 (estimated)
- First submitted
- 19 Oct 2026
- Start date
- 8 Oct 2026
- Primary completion date
- 30 Nov 2029
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Diseases
- Prostate cancer
- NCT number
- NCT07910019
What you commit to
- Study type: Observational
- Planned participants: 45
- From 8 Oct 2026 to the primary completion date, 30 Nov 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- AIM 1:
- Inability or unwillingness to give written informed consent
Who the study is looking for
- AIM 1:
- Diagnosis (or presumed diagnosis) of primary Prostate cancer
- 18 years of age or older
- Has a planned visit to a University of Minnesota Cancer Clinic
- Willing and able to sign voluntary written consent
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Minnesota/Masonic Cancer Center Coordinator of this site? Confirm its status | Minneapolis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.